Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.10
Ask: 2.19
Change: 0.035 (1.66%)
Spread: 0.09 (4.286%)
Open: 2.06
High: 2.15
Low: 2.06
Prev. Close: 2.11
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

Mon, 25th Mar 2024 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug discovery and development company updates on Incanthera PLC's commercial skincare deal, announced in December 2023, with Marionnaud, part of the AS Watson Group. Says the first order from Marionnaud has now doubled to 50,000 units due to the strong demand anticipated by Marionnaud's management. The first order, on track to be delivered during the second quarter of 2024, will generate around GBP2 million in revenue for Incanthera, ImmuPharma said. ImmunPharma holds an 11% stake in Incanthera. ImmuPharma Chief Operating Officer Tim Franklin comments: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."

----------

Caspian Sunrise PLC, up 26% at 3.28p, 12-month range 2.20p-7.49p. The Kazakhstan-focused oil and gas exploration and production company said it was mulling the sale of all or part of the BNG contract area's shallow structures at "indicative prices potentially significantly greater than its current carrying value". Says any deal would likely require shareholder approval due to its size of the transaction value relative to the group. "We believe this heightened level of corporate interest in BNG's producing shallow structures is in part the result of the changes last year to the Kazakh oil trading regulations, which now require the production of oil to obtain a trading licence, and the relative scarcity of producing fields with full production licences. The sharp reduction in the discount for international sales referred to below may also have had an effect," the company says. Caspian Sunrise says no binding agreements have been entered into and there is no certainty that discussions will lead to a firm offer or that the board would put an offer before shareholders.

----------

AIM - LOSERS

----------

Aeorema Communications PLC, down 19% at 60.5p, 12-month range 55.00p-119.40p. In the six months that ended December 31, swings to pretax loss of GBP243,534 from a profit of GBP326,021 a year earlier. Revenue falls to GBP6.6 million from GBP7.1 million, while administrative expenses rise to GBP1.7 million from GBP1.2 million. Expects full-year revenue of no less than GBP19 million compared to GBP20.2 million in the financial year that ended June 30, 2023. Chair Mike Hale comments: "With a focus on adaptability and forward planning, Aeorema is well positioned for the future and is confident in its ability to deliver sustainable growth and value creation over the long term. We also expect to reaffirm our commitment to shareholders by maintaining our dividend policy. While this half year's financial performance reflects the impact of project timing, we are encouraged by the underlying strength of our business and our pipeline. Our focus remains steadfast on delivering creative brilliance for our clients on a global scale, and sustained growth and value to our shareholders."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
21 Oct 2014 11:19

UK MIDDAY BRIEFING: GKN A Winner As Earnings Season Hits Full Swing

Read more
21 Oct 2014 11:16

Immupharma raises £3.4m as it gears up for Lupuzor Phase III trial

Shares in drug developer Immupharma were higher after confirmation it had raised £3.4m at a premium price to help fund Phase III trials of its lead product candidate Lupuzor, a potential treatment for lupus. The new shares were issued, principally from long-time investor Aviva, at a price of 53p per

Read more
21 Oct 2014 11:00

UK WINNERS & LOSERS: ASOS Back In Style Despite Profit Fall

Read more
20 Oct 2014 06:59

ImmuPharma Gets EUR400,000 Grant In France For Urelix Technology

Read more
5 Oct 2014 13:32

Sunday share tips: BG Group, Genel Energy, Palace Capital

Sell shares of BG Group, Danny Fortson advised in the Sunday Times. Credit Suisse analysts have questioned whether the gas producer's big Australian operation will open on time and have said BG's estimates for its Brazilian oil fields are bigger than those of Petrobas, which leads the development. I

Read more
30 Sep 2014 09:27

ImmuPharma Poised For Phase III Trials Of Lupuzor As Loss As Expected

Read more
27 Jun 2014 12:10

ImmuPharma Forms European Research Team As Part Of Peptides Drive

Read more
16 Jun 2014 10:52

ImmuPharma Granted New US Patent For Nucant Cancer Treatments

LONDON (Alliance News) - ImmuPharma PLC said Monday that it had been granted a US patent for a new "optically pure" version of its Nucant family of cancer treatments, providing it with longer exclusivity over the product, and expanding their potential uses to related conditions such as age-relate

Read more
16 Jun 2014 08:14

Immupharma gains new patents for Nucant treatments

Drug developer Immupharma has improved the patent protection of its Nucant cancer treatments. Immupharma said the US Patent and Trademark Office has granted a notice of allowance for an "optically pure" version of its Nucant family. A similar grant has been obtained from the European Union, Japane

Read more
21 May 2014 13:14

ImmuPharma's patient approach disappoints

Losses from AIM-listed biotech ImmuPharma were less than expected, with the company working hard to commercialise its Lupuzor lupus treatment via phase III clinical trials and new potential partners. Lupuzor has received approval from the US Food and Drug Administration (FDA) to start late-stage t

Read more
21 May 2014 11:45

ImmuPharma Losses Widen As It Accelerates Research And Development

LONDON (Alliance News) - Specialist drug discovery and development company ImmuPharma PLC Wednesday said it losses widened in 2013, as its invests in developing its lupus and cancer treatments. The company posted pretax profit loss of GBP4.4 million for 2013, compared with a GBP4.2 million

Read more
27 Sep 2013 12:23

ImmuPharma Narrows Losses, Developing Lupus Treatment

Read more
27 Sep 2013 10:30

ImmuPharma reports half-year loss

ImmuPharma's shares fell in Friday morning trading as the company reported a half-year loss in line with last year. Losses for the first six months of the year remained unchanged at £1.8m and loss per share held steady at 2.17p. The drug discovery and development company said during the period it

Read more
13 Aug 2013 09:17

Immupharma progresses with cancer treatment trials

ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients. IPP-204106 is 10 times more efficient that the previous Nucant version in p

Read more
28 Jan 2013 16:06

ImmuPharma non-exec reduces stake

Dr Ajay Agrawal, Non-Executive Director of ImmuPharma, sold a stack of shares in the AIM-listed drug company, it was announced Monday. Agrawal traded in 62,169 shares at 57p a time on January 24th, pocketing £35,436 before tax. The deal was announced the same day the group said its key scientific

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.